Skip to main content
. 2016 Nov 28;45(6):e39. doi: 10.1093/nar/gkw1166

Figure 4.

Figure 4.

Application of MS-NaME in clinical tumor and plasma samples. Lung tumor samples were treated with (A) four-plex and (B) 177-plex MS-NaME treatment and measured with RARb2 digital Methylight to quantify the methylation ratio change. Plasma circulating-DNA samples from two healthy donors (#21 and #25) which were unmethylated in ATM promtoter were spiked with 1% or 10% methylated DNA (final ratio), and then treated by 177-plex MS-NaME. Error bars represent the standard error of the mean from two independent experiments. (C) ATM MS-HRM was applied to sample 21a. The melting curves are as follows: 1% spike-in-No DSN-green, 1% spike-in-MS-NaME-green with square symbol, 10% spike-in-No DSN-red, 10% spike-in-MS-NaME-red with square symbol. (D) ATM digital Methylight was applied to plasma DNA samples 21a, 21b, 25a and 25b. a and b denote samples taken from the same healthy donor but spiked with different amounts of methylated DNA. Error bars represent the standard error of the mean from two independent experiments.